| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Pulmonary and Critical Care Divisions, Dept of Medicine, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, and 2 Critical Care Division, Policlínico Alejandro Posadas, Haedo, Provincia de Buenos Aires, Argentina. 3 Dept of Medicine and Pulmonary and Critical Care Division, Winthrop University Hospital, Mineola, NY, USA.
CORRESPONDENCE: C. M. Luna, Acevedo 1070, Banfield, 1828, Buenos Aires, Argentina. Fax: 54 1142026068. E-mail: cymluna{at}fmed.uba.ar
Keywords: Adequate therapy, antimicrobials, delayed therapy, nosocomial pneumonia, outcome, resistant pathogens
Received: April 23, 2005
Accepted August 12, 2005
 |
ABSTRACT |
|---|
 TOP ABSTRACT METHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
Appropriate therapy was defined as coverage of all the identified pathogens by the antimicrobial therapy administered at the time of VAP clinical diagnosis. The clinical pulmonary infection score was measured during the 3 days before, at the onset and during the days which followed the onset of VAP. A total of 24 patients received adequate therapy; mortality was 29.2%. The remaining 52 patients received either IT (n = 16) or DIAT (n = 36); the mortality was 63.5% combined, and 75.0 and 58.3% for IT and DIAT, respectively (statistically significant compared with adequate therapy).
Inappropriate therapy and delayed initiation of appropriate therapy increased the mortality of ventilator-associated pneumonia. Patients with inappropriate therapy and/or delayed initiation of appropriate therapy had a more gradual increase in clinical pulmonary infection score than those receiving adequate therapy, and this increase was found to occur prior to the time of the clinical diagnosis.
In conclusion, these findings might provide the rationale for a trial of earlier initiation of therapy, based on clinical grounds in an effort to improve the outcome of patients with ventilator-associated pneumonia.
Ventilator-associated pneumonia (VAP) is a frequent infectious complication among patients admitted to the intensive care unit (ICU), increasing the risk of death 1. Outcome studies indicate that there are several factors related to mortality in VAP 2–6. Delay in the initiation of therapy in pneumonia increases the risk of death in both community-acquired and nosocomial pneumonia 7, 8. The clinical pulmonary infection score (CPIS) was described to improve the clinical diagnosis of VAP, by including several criteria to quantify evidence of pneumonia 9. CPIS has been used to evaluate the response to therapy, to select patients for a short course of antibiotics and to predict VAP outcome, when performed in a serial fashion 7, 8, 10–12. Even though the sensitivity of the CPIS identification for bacteriologically confirmed VAP has been found to be
90% 9, it has a low diagnostic accuracy and is not superior or more accurate than the clinical prediction 13, 14. In one study, patients with a CPIS 
6 were treated successfully with only 3 days of antibiotic therapy 10. These findings raised the question as to whether such a short duration was possible because of the initiation of therapy at the earliest time possible, or whether some of these patients actually did not have VAP. If the former explanation is correct, then patients may benefit from early recognition and therapy of VAP. Therefore, it was hypothesised that serial measurements of the CPIS in mechanically ventilated patients could be used, more precisely, to define the optimum time to start therapy for pneumonia patients in comparison with the use of standard clinical diagnosis. Taking into account the antibiotic susceptibility data for patients with VAP to define appropriate therapy (AT), measurements were taken of how often patients received AT, and how often such therapy was initiated in a delayed fashion, using the CPIS as a sensitive tool to define the best time to start therapy of VAP. Knowing more clearly the number of patients receiving inappropriate therapy (IT) or delayed initiation of appropriate therapy (DIAT), the impact of therapy given in this manner was defined.
|
METHODS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
18 yrs and have an estimated length of ventilation >72 h. Exclusion criteria were: admission after referral from another ICU; nosocomial pneumonia at the time of admission; and an AIDS-defining condition or neutropaenia (<1,000·mm–3). The ethics committees from the participating institutions approved the study.
The data collected included the following: reason for admission; past medical history; vital signs; laboratory data; and chest radiographs, allowing for a calculation of a previously described modified version of the CPIS 9. CPIS was calculated every day from the onset of mechanical ventilation up to the patient's discharge or death. In this modified CPIS (table 1
), a tracheal aspirate culture was excluded as it was not available in time; leukocyte categories were reduced to two (>5% of band forms were not considered because this information was not always available); and three categories instead of two were used for the aspect of sputum, to obtain a maximum of 10 points for the CPIS score 12. The CPIS was calculated by one of two members of the investigation team (C.M. Luna or F. Ríos). Verification of data was performed before processing.
|
A time-dependent analysis of the CPIS score was conducted for patients developing VAP. The time points were as follows: 3, 2, and 1 days before the onset of VAP (VAP-3, -2 and -1); the onset of VAP (VAP); and 3–7 days after the onset of VAP (VAP+3, +5 and +7).
VAP patients were followed daily until pneumonia was cured (discontinuation of antimicrobials or 21 days of antimicrobial therapy, whichever happened first), hospital discharge or death.
Definitions
Pneumonia was defined as new and persistent radiographical infiltrate(s) plus two of the following: 1) body temperature >38°C or <36°C; 2) white blood cells >10,000 or <4,000·mm–3; or 3) macroscopically purulent tracheal aspirate 4. Additionally, it was required that patients have microbiological confirmation, i.e. by growth of 104 colony forming units (cfu)·mL–1 taken from a bronchoscopic BAL culture or isolation of a potential pathogen from the blood culture (unrelated to another source), and prescription of antimicrobials for pneumonia, after the clinical diagnosis.
The definition for the day of onset of VAP was the day that the attending physicians made the clinical diagnosis and prescribed antimicrobials for VAP, in patients fulfilling the clinical criteria of VAP.
Prior antimicrobial treatment was declared if there was current use of antimicrobials at the time of diagnosis of VAP, or previous use for >24 h during the 10 days prior to VAP diagnosis. Indications for prior antimicrobials are listed in table 2.
|
104 cfu·mL–1 on BAL culture), by the antimicrobial therapy administered at the onset of VAP, determined by the sensitivity pattern in the antibiogram. AT could be adequate or not according to definitions published elsewhere 15.
Inadequate therapy involved not only IT (lack of coverage of all the pathogens isolated), but also DIAT. DIAT was defined as being present if AT was given within 24 h of the clinical diagnosis of VAP but also if the patient had a CPIS 5 on the day before the clinical diagnosis was made (VAP-1). This definition was chosen as all of these VAP episodes were microbiologically defined, and if the CPIS had been calculated according to Pugin et al. 9, they would have received two more points for a positive respiratory culture, giving a score of 7, which is consistent with the presence of VAP. This definition allowed the current authors to test the hypothesis that these patients actually had VAP that was present before the time that it was recognised by standard clinical criteria, and that they might have benefited from earlier therapy. Thus, the inadequate therapy group included those with treatment delays due to a lack of sensitivity of the clinical diagnosis compared to the CPIS (DIAT), and those whose initial empirical antimicrobial treatment provided a lack of coverage of the aetiological pathogen (IT).
Outcome criteria
Mortality at day 28 after the VAP onset during hospitalisation was the main outcome criteria used. The length of stay and the days on antimicrobial therapy for VAP in survivors were also observed.
Statistical analysis
Continuous variables are expressed as mean±SEM, unless stated otherwise. Statistical significance was determined using an unpaired t-test. Differences between patients receiving adequate therapy and those receiving IT or DIAT were tested by two-way repeated measures ANOVA, and post hoc comparisons at specific time points were made by t-test with Bonferroni's correction. The Fisher's exact test was used to compare categorical variables. Significance was accepted for p-values <0.05.
|
RESULTS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
. In 15 cases, more than one pathogen was isolated (92 pathogens for 76 cases, i.e. 1.21 pathogens per case). The incidence rate of pneumonia was 14.9 per 100 mechanically ventilated patients.
|
Serial evaluation of clinical pulmonary infection score
A time-dependent analysis of the CPIS was conducted for the overall population and independently for the patients receiving adequate therapy and those receiving either IT or DIAT. During the days prior to the clinical diagnosis of VAP, the CPIS rose from VAP-3 to VAP (5.0±0.3 versus 6.7±0.2; p<0.001); thereafter, during the following days, the CPIS fell from VAP to VAP+3 (6.7±0.2 versus 6.1±0.2; p = 0.028) in the population as a whole. Comparing adequate therapy (n = 24) with IT-DIAT (n = 52), the CPIS score was similar in both groups at the VAP-3 (4.6±0.5 versus 5.2±0.3; p = 0.273) and VAP (6.4±0.4 versus 6.9±0.2; p = 0.209) time points. However, the CPIS was higher, and rose more gradually toward a peak value, in the IT-DIAT patients compared with the patients who had been given adequate therapy, at VAP-2 (5.5±0.3 versus 4.2±0.3; p = 0.008) and VAP-1 (6.1±0.2 versus 3.9±0.3; p = 0.005; fig. 1). Thus, two separate populations were identified: one with adequate therapy who had a sudden rise in CPIS at the same time as the clinical diagnosis of VAP and received AT in a timely fashion; and one with IT-DIAT, who had a gradual rise in CPIS prior to the clinical diagnosis of VAP and received IT-DIAT. After the VAP time point, the CPIS exhibited a similar behaviour independent of the adequacy of therapy: CPIS for adequate therapy and IT-DIAT was 6.2±0.4 versus 6.1±0.2 at VAP+3 time point (p = 0.879; fig. 1). CPIS was 5.8±0.4 versus 5.8±0.3 at VAP+5 and 5.8±0.4 versus 5.8±0.3 at VAP+7 time points (p = 0.962 and 0.883, respectively; data not shown).
|
). The current authors examined mortality in relation to whether the therapy at the time of clinical suspicion of VAP was considered adequate or IT-DIAT.
The overall mortality rate was 52.6%. In the group receiving adequate therapy, the mortality rate was 29.2%, whereas it was 63.5% for those receiving inadequate therapy (75.0% for IT and 58.3% for DIAT) giving p-values of 0.007, 0.009 and 0.036, respectively, when compared with the adequate therapy group (fig. 2). There were no differences in the following: age; Acute Physiology and Chronic Health Evaluation (APACHE II) at admission; reason for mechanical ventilation; pathogens; days on prior mechanical ventilation or time from VAP onset and weaning or death, between adequate therapy and IT-DIAT (tables 4 and 5).
|
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
, to define clinical criteria for earlier initiation of therapy that could potentially lead to a reduction in VAP mortality. The failure of initial antibiotic therapy due to the presence of resistant pathogens is one of the most important causes of poor outcome 20, 21. Adequacy of initial antimicrobial therapy is a major prognostic factor for patients with VAP. Thus, before new antibiotics are administered, reliable pulmonary specimens must be obtained for microbial examination 22. In a previous study, a simplified CPIS score and its components were used to define the natural history VAP resolution and demonstrate that this approach can help to define early failure to response 12.
In the present study, the incidence of microbiologically confirmed VAP was 14.9%. Similar to previous reports, approximately three-quarters of the patients involved in the study were on antibiotics at the time of VAP diagnosis 23, 24. The patients were divided on the basis of the adequacy of initial empirical antibiotic therapy and the evolution of the CPIS from 3 days before, up to 7 days after the onset of VAP was examined. In 36 patients who received appropriate empirical antibiotic therapy after the clinical suspicion of VAP, there was a delay in the initiation of therapy. This delay was defined as an appropriate treatment given within 24 h of the clinical diagnosis in patients who had a CPIS of 5 for at least 24 h before the initiation of therapy. A CPIS of 5 was chosen to define the correct time to start therapy, even if it occurred prior to when a clinical diagnosis was made. This was done as all these patients had VAP confirmed by BAL culture, and thus would have had a CPIS of >6 if microbiological criteria had been used, as originally described by Pugin et al. 9. The 36 patients with DIAT were pooled with the 16 patients who received initially empirical IT, and this IT-DIAT group consisted of all the patients who received inadequate antibiotic therapy.
It was observed (fig. 1) that at a time prior to the clinical diagnosis of VAP, the CPIS score was significantly higher at days VAP-2 and VAP-1 in the group of patients on IT-DIAT, compared with those receiving adequate therapy. It was also observed that there was no difference in the CPIS between the VAP and VAP+3, +5 or +7 time points, when patients on adequate therapy were compared with those on IT-DIAT. However, the IT-DIAT group had a gradual rise in CPIS to a peak value, whereas those in the adequate therapy group had a sudden rise. Thus, those patients who had undergone a rapid clinical deterioration prior to the clinical diagnosis of VAP, as reflected by the CPIS, had timely initiation of therapy, possibly because the sudden change in clinical status facilitated the timely clinical recognition of pneumonia. However, for those with a more gradual rise in CPIS, it is believed that they all had VAP for 24 h prior to the clinical recognition of infection, and that the slow rise in CPIS, reflecting a more gradual deterioration, may have led to a delay in therapy for some. Since patients with adequate therapy had a better outcome than those with IT-DIAT, it is possible that earlier initiation of therapy could have had value for this latter group. In fact, when Singh et al. 10 gave therapy to patients with a CPIS of 6, they were able to treat patients for as few as 3 days, implying that early therapy can be more effective than delayed therapy. However, an alternative interpretation could be that following the CPIS criteria may be misleading, especially since the score improved at VAP-2 and VAP-1 in the adequately treated patients, and this may reflect a lack of sensitivity and specificity of CPIS to define the onset of pneumonia.
In a retrospective, cohort study on patients with ICU-acquired bacteraemic nosocomial infection or pneumonia, Mathevon et al. 25 observed that the mortality rate was significantly associated with the length of time without appropriate antibiotic treatment (p = 0.011) and the number of organ failures on the day of diagnosis (p = 0.017). Appropriate antibiotic treatment only had an impact on survival if it was started within the first 24 h after sampling (p<0.02 on day 0 and <0.04 on day 1). This difference remained after adjusting for the number of organ failures. This suggests that, during the course of nosocomial pneumonia and bacteraemia, the time at which appropriate antibiotic treatment is started is a key factor influencing survival 25. This has also been demonstrated for S. aureus sepsis 26.
In a previous study, it was observed that when patients received antibiotics before the clinical suspicion of VAP, mortality was reduced if this previous therapy was appropriate, compared with when this therapy was inappropriate or if no therapy was given 4. Changing from IT to AT, based on the results of BAL, did not reduce the mortality, as it was comparable with those who continued to receive IT, and this information became available too late to influence survival 4. Thus, if AT was delayed, mortality was higher. In another study, it was observed that the combination of a nonimproving CPIS and inappropriate empirical therapy could identify a population that is unlikely to improve, regardless of changes in therapy, while this may not be true for patients who showed a favourable early response, in spite of IT 12. In this prior study, a significant difference in the CPIS value between survivors and nonsurvivors during the 5 days following VAP onset was observed. Similar to the authors' prior study, in the current study, patients receiving IT-DIAT had a mortality of 77% if the CPIS remained 5 during the 5 days after VAP onset, and 31% when the CPIS was <5 (p = 0.01), whereas in those receiving adequate therapy, mortality was 46% when the CPIS remained 5 and 11% when CPIS was <5 (p = 0.165; data not shown).
Another recent study addressed the clinical importance of delays in the initiation of appropriate antibiotic treatment for VAP 8. The study by Iregui et al. 8 found a statistically significant association between the delay in administration of AT and hospital mortality for patients with VAP. Multiple logistic regression analysis identified this delay, increasing severity of illness as measured by APACHE II scores and the presence of underlying malignancy as important determinants of hospital mortality.
The current findings, which related the adequacy of therapy to the time of initiating therapy, confirmed that early initiation of AT may improve the survival of patients with VAP and that a more sensitive tool than clinical diagnosis may be needed to define the optimal time to initiate therapy in an effort to alter the course of illness. The present study's data show that the most sensitive criterion for defining this time point may be when the modified CPIS (table 1) reaches 5, which, in some patients, occurred even prior to the clinical diagnosis of VAP.
To summarise, the authors conducted a prospective evaluation of the natural history of ventilator-associated pneumonia during therapy in patients that received both adequate therapy and inadequate therapy. While other studies have looked at the adequacy of therapy at the time of clinical suspicion of ventilator-associated pneumonia, there is only one study that related the timing of the administration of appropriate therapy to the time of onset of symptoms 8, and, to the current authors' knowledge, this is the first study that has prospectively evaluated the evolution of the clinical pulmonary infection score and used these data to define delayed initiation of appropriate therapy. The current study's findings suggest that serial measurements of the clinical pulmonary infection score in mechanically ventilated patients could be used to identify patients developing pneumonia that was not yet clinically recognised. Since the mortality of patients with inappropriate therapy or delayed initiation of appropriate therapy differed from patients with adequate therapy, the authors believe that an earlier initiation of appropriate therapy, guided by the clinical pulmonary infection score or another clinical score, could lead to an improved outcome of patients with ventilator-associated pneumonia. However, this is still a hypothesis that could be tested in subsequent clinical trials to define the optimal time to initiate antibiotic therapy.
|
ACKNOWLEDGEMENTS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  H. Kothe, T. Bauer, R. Marre, N. Suttorp, T. Welte, K. Dalhoff, and the Competence Network for Community-Acquired Pneu Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment Eur. Respir. J., July 1, 2008; 32(1): 139 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Visscher, E. M. Kruisheer, C. A. M. Schurink, P. J. F. Lucas, and M. J. M. Bonten Predicting pathogens causing ventilator-associated pneumonia using a Bayesian network model J. Antimicrob. Chemother., July 1, 2008; 62(1): 184 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Parkins, D. M. Sabuda, S. Elsayed, and K. B. Laupland Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections J. Antimicrob. Chemother., September 1, 2007; 60(3): 613 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Curcio and F. Fernandez Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective J. Antimicrob. Chemother., August 1, 2007; 60(2): 449 - 450. [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Luna, S. Baquero, S. Gando, J. R. Patron, J. G. Morato, O. Sibila, R. Absi, A. Famiglietti, C. A. Vay, F. Von Stecher, et al. Experimental Severe Pseudomonas aeruginosa Pneumonia and Antibiotic Therapy in Piglets Receiving Mechanical Ventilation Chest, August 1, 2007; 132(2): 523 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Curcio, F. Fernandez, R. N. Jones, M. J. Ferraro, L. B. Reller, P. C. Schreckenberger, and H. S. Sader Tigecycline Disk Diffusion Breakpoints of Acinetobacter spp.: a Clinical Point of View J. Clin. Microbiol., June 1, 2007; 45(6): 2095 - 2096. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
; p = 0.0083 and 0.0051, respectively). After VAP onset, the CPIS was the same at the VAP+3 time point for both groups.